The leading explanation for why obstructive sleep apnea damages the heart has always centered on the airways: repeated oxygen drops trigger blood pressure spikes, stress hormones surge, and inflammation accumulates in arterial walls. A study presented at ASM Microbe 2026 adds a surprising new chapter to that story — one that begins in the gut.
Researchers found that sleep apnea-like conditions reshape the gut microbiome, alter bile acid signaling, and drive atherosclerosis through a specific bile acid receptor called the farnesoid X receptor (FXR). When FXR was genetically removed in mice, the arterial plaque buildup caused by simulated sleep apnea was abolished.
The Experiment
The team used two groups of mice genetically predisposed to heart disease: standard ApoE knockout mice (a widely used model for atherosclerosis) and ApoE/FXR double knockout mice that lacked both the cardiovascular vulnerability gene and the bile acid receptor. Both groups were fed a high-fat, high-cholesterol diet for 10 weeks while being exposed to either normal room air or intermittent hypoxia and hypercapnia (IHC) — a laboratory model that replicates the cyclical oxygen drops and carbon dioxide spikes of obstructive sleep apnea.
Researchers tracked gut microbiome changes through fecal samples during the study and measured arterial plaque burden at the end.
A Gut-Driven Pathway to Plaque
In the standard ApoE knockout mice, IHC exposure markedly increased atherosclerotic plaque in the aorta and aortic arch — the body's main arteries. That finding was expected; sleep apnea is already known to accelerate cardiovascular disease.
The surprise came from the double knockout mice. Without FXR, the sleep apnea-driven increase in arterial plaque was effectively eliminated. Their gut microbiomes were also less disrupted, and the bile acid profile remained closer to that of mice breathing normal air.
The mechanism appears to work like this: when sleep apnea deprives the body of oxygen, it reshapes the gut microbial community, promoting the growth of bacteria that produce specific bile acid-modifying enzymes — particularly microbial hydroxysteroid dehydrogenase (HSDH). These microbially modified bile acids travel through the bloodstream and activate FXR receptors throughout the cardiovascular system, triggering the accumulation of fatty plaques in the arteries.
Why This Matters Beyond Mice
The findings are significant because they identify a specific, potentially druggable target in the chain of events linking sleep apnea to heart disease. FXR modulators already exist — some are being developed for liver disease — which means the pharmaceutical infrastructure to test this approach in humans is partially in place.
The study is also among the first to demonstrate that the gut microbiome and the bile acids it modifies represent a viable alternative point of intervention for sleep apnea-related cardiovascular damage. Rather than treating the airway obstruction alone, future therapies could potentially target the downstream metabolic consequences.
The research team has indicated plans to explore supplementation with specific protective bile acids and the use of beneficial microbes as preventive probiotics — approaches that could eventually be paired with existing treatments like CPAP.
Limitations
This is a mouse study, and the leap from FXR knockout mice to human therapy is large. The IHC model simulates the oxygen fluctuations of sleep apnea but does not perfectly replicate the condition. Human bile acid metabolism is also more complex than that of mice, and FXR plays roles in liver function and glucose regulation that would need to be carefully managed in any therapeutic approach.
What This Means for Patients
For the estimated 936 million people worldwide with obstructive sleep apnea, this study does not change treatment today — but it changes the conversation about where treatment might go. The finding that a gut-level receptor drives much of the arterial damage from sleep apnea opens a research avenue that is entirely distinct from the current focus on keeping airways open during sleep.
Patients who are already managing their sleep apnea with CPAP or oral appliances should continue doing so. But those with cardiovascular risk factors may eventually benefit from therapies that address what this study suggests is a hidden second front in sleep apnea's assault on the heart — one that runs through the gut.
